HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Pentostatin (Nipent)

Subscribe to New Research on Pentostatin

A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.

Also Known As:

Nipent; CI-825; Co-Vidarabine; Deoxycoformycin; Lederle Brand of Pentostatin; NSC-218321; Prasfarma Brand of Pentostatin; Supergen Brand of Pentostatin; Warner-Lambert Brand of Pentostatin; Wyeth Brand of Pentostatin; 2' Deoxycoformycin; CI 825; CI825; Co Vidarabine; NSC 218321; NSC218321; 2'-Deoxycoformycin; Imidazo(4,5-d)(1,3)diazepin-8-ol, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (R)-

Networked: 403 relevant articles (52 outcomes, 74 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Grever, Michael R: 13 articles (01/2015 - 03/2003)
2.	Byrd, John C: 8 articles (01/2015 - 04/2005)
3.	Kay, Neil E: 7 articles (09/2015 - 01/2004)
4.	Ravandi, Farhad: 6 articles (12/2015 - 01/2006)
5.	Vogelsang, Georgia B: 6 articles (11/2009 - 07/2003)
6.	Call, Timothy G: 5 articles (09/2015 - 01/2007)
7.	Shanafelt, Tait D: 5 articles (09/2015 - 01/2007)
8.	Zent, Clive S: 5 articles (07/2014 - 01/2007)
9.	Catovsky, Daniel: 5 articles (06/2011 - 10/2003)
10.	Matutes, Estella: 5 articles (06/2011 - 10/2003)

Related Diseases

1.	Hairy Cell Leukemia 01/01/2003 - "Pentostatin is a highly effective regimen for hairy cell leukemia that produces durable complete responses. " 07/01/2001 - "Although most patients with hairy cell leukemia in Japan have the Japanese variant, and the European-American type is rare, pentostatin is as effective as it is for European and American patients." 11/01/2000 - "Pentostatin is a highly effective regimen for hairy cell leukemia that produces durable complete responses. " 04/01/2000 - "Pentostatin is a highly effective agent for hairy cell leukemia and produces prolonged remissions in the majority of patients." 11/01/1986 - "Low-dose deoxycoformycin administered intravenously every other week represents an extremely effective treatment for hairy cell leukemia."
2.	Leukemia 04/01/2006 - "Early clinical trials with pentostatin used high doses for acute lymphoblastic leukemias, which were characterized by high levels of ADA. " 01/01/1987 - "Biochemical mechanisms of deoxycoformycin toxicity in chronic leukemias." 01/01/1984 - "Biochemical basis for the differential effects of deoxycoformycin on human leukemias." 01/01/1984 - "We examined the in vivo effects of a potent inhibitor of ADA, 2'-deoxycoformycin, which was used to treat a patient with refractory acute leukemia. " 10/01/1983 - "Increased cytotoxicity of N6-(delta 2-isopentenyl)adenosine in combination with pentostatin against L-1210 leukemia cells."
3.	Lymphoma (Lymphomas) 06/01/1988 - "Promising results in the treatment of indolent lymphomas have been reported with the use of 2'deoxycoformycin. " 03/01/1996 - "Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group." 04/01/1991 - "Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease." 09/01/2003 - "Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes." 07/15/1991 - "Transport of 2'-deoxycoformycin in human leukemic and lymphoma cells."
4.	Neoplasms (Cancer) 08/01/2002 - "The pentostatin doses used in the study appear to be appropriate for administration to cancer patients with varying degrees of renal impairment." 03/01/2005 - "Present and previous data reviewed here demonstrates the striking cytotoxic activity of Pentostatin against gammadelta+ tumor T cells. " 01/01/1996 - "It was anticipated that pentostatin would be most active in neoplasms with high intracellular concentrations of ADA, e.g. " 01/01/1996 - "It was hypothesized that pentostatin would be lymphocytotoxic and this proved to be true; this finding prompted its investigation in lymphoid neoplasms. " 09/01/1990 - "Pentostatin (2'-deoxycoformycin) for the treatment of lymphoid neoplasms."
5.	Splenomegaly 11/01/1992 - "After administration of deoxycoformycin (DCF) at a dose of 5.0mg/m2 1-2 times monthly, splenomegaly disappeared, as did hairy cells from the peripheral blood. " 05/01/2001 - "[European-American-type hairy cell leukemia without splenomegaly, treated successfully with deoxycoformycin]." 12/01/1984 - "A woman with hairy-cell leukemia has begun treatment with pentostatin, and at ten weeks there is disappearance of gross splenomegaly and clearance of hairy cells from the blood. " 04/01/1995 - "A multivariate logistic regression analysis of the confirmed complete remissions on pentostatin showed the following factors to be important for achieving a complete remission: high hemoglobin level (two-tailed P = .024), young age (P = .0085), and no or little splenomegaly (P = .0029). "

Related Drugs and Biologics

1.	Cladribine
2.	Pentostatin (Nipent)
3.	Adenosine Deaminase
4.	Interferon-alpha (Interferon Alfa)
5.	purine
6.	rituximab (Mabthera)
7.	Cyclophosphamide (Cytoxan)
8.	Interferons
9.	fludarabine
10.	Deoxyadenosines (Deoxyadenosine)

Related Therapies and Procedures

1.	Splenectomy
2.	Transplants (Transplant)
3.	Aftercare (After-Treatment)
4.	Drug Therapy (Chemotherapy)
5.	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)